Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMVERM vs CARISOPRODOL AND ASPIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Treatment of trichuriasis (whipworm infection),Treatment of enterobiasis (pinworm infection),Treatment of ascariasis (roundworm infection),Treatment of hookworm infections (Ancylostoma duodenale and Necator americanus),Off-label: Treatment of capillariasis, toxocariasis, and other helminth infections
Relief of discomfort associated with acute painful musculoskeletal conditions
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Primarily hepatic; metabolized by microsomal enzymes (CYP450) to major metabolite 2-aminomebendazole, which is less active; also undergoes further metabolism.
Carisoprodol is N-deacetylated via CYP2C19 to meprobamate, a schedule IV controlled substance. Aspirin is hydrolyzed to salicylic acid in the liver and gastrointestinal tract.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
~90-95% bound to plasma proteins, primarily albumin.
Carisoprodol: ~60% bound to albumin. Aspirin: 80-90% bound to albumin (salicylate); highly protein-bound at therapeutic concentrations.
~1-2 L/kg; indicates extensive tissue distribution.
Carisoprodol: ~0.7 L/kg (large Vd, extensive tissue distribution). Aspirin: ~0.15 L/kg (salicylate; low Vd, primarily in extracellular fluid). Clinical meaning: Carisoprodol distributes into CNS and muscle; aspirin remains largely in plasma and interstitial space.
Oral: ~22-40% due to first-pass metabolism; improved with food.
Oral: Carisoprodol: ~90% (well absorbed). Aspirin: ~40-50% (presystemic hydrolysis in GI mucosa and liver; rectal: 100% absorbed, but avoids first-pass).
No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
e GFR 30-59 m L/min: avoid or reduce dose; e GFR <30 m L/min: contraindicated.
No adjustment for mild (Child-Pugh A) or moderate (Child-Pugh B) impairment. Avoid use in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
Child-Pugh Class A: caution; Class B or C: contraindicated.
Children ≥2 years: 100 mg orally twice daily for 3 days. Children <2 years: safety not established; use only if potential benefit outweighs risk.
Not recommended for pediatric patients under 12 years of age. For older adolescents, weight-based dosing of aspirin 10-15 mg/kg/dose every 4-6 hours (max 80 mg/kg/day) and carisoprodol 5-10 mg/kg/dose three times daily; avoid routine use due to risk of Reye's syndrome.
No specific adjustment required; use standard adult dosing. Monitor for adverse effects due to potential age-related renal or hepatic decline.
Initiate at lowest effective dose; monitor for CNS depression, renal function, and bleeding risk. Avoid in patients with significant renal impairment or peptic ulcer disease.
None.
None.
Risk of neutropenia and agranulocytosis, especially with high doses or prolonged use,May cause bone marrow suppression; monitor blood counts in prolonged therapy,Hepatotoxicity reported; use caution in hepatic impairment,Seizures have occurred, particularly in patients with history of seizures,Not recommended in pregnancy (pregnancy category C); embryotoxic and teratogenic in animals
Dependence and withdrawal: Carisoprodol may cause dependence and withdrawal symptoms.,Sedation and CNS depression: Additive effects with alcohol and other CNS depressants.,Reye's syndrome: Aspirin use in children and teenagers with viral illness.,Gastrointestinal bleeding: Aspirin increases risk of GI bleeding.,Hypersensitivity reactions: Anaphylaxis, angioedema.
Hypersensitivity to mebendazole or any component of the formulation,Absolute contraindication: Known hypersensitivity
Hypersensitivity to carisoprodol or aspirin.,Children and teenagers with viral infections (Reye's syndrome risk).,Active peptic ulcer disease or GI bleeding.,Severe hepatic impairment.,History of asthma induced by aspirin or NSAIDs.,Concomitant use with meprobamate-containing products.
No significant food interactions; absorption is enhanced by fatty foods but not required for efficacy in enterobiasis. Avoid alcohol due to potential hepatotoxicity.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid high-tyramine foods (e.g., aged cheese, cured meats) as aspirin may potentiate tyramine effects.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed. Risk cannot be ruled out, especially in the first trimester.
First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk of premature closure of ductus arteriosus and oligohydramnios; carisoprodol not well studied but may cause neonatal withdrawal. Avoid in third trimester due to aspirin's antiprostaglandin effects.
Excretion in human milk unknown. Caution should be exercised when administered to a nursing woman. M/P ratio not available.
Aspirin and carisoprodol are excreted into breast milk. M/P ratio for aspirin is approximately 0.6-0.9; carisoprodol M/P ratio not established. Risk of Reye syndrome with aspirin, neonatal salicylate accumulation, and sedation from carisoprodol. Use not recommended during breastfeeding.
No dose adjustment is recommended solely due to pregnancy, as pharmacokinetic changes are not well characterized. Use standard dosing: mebendazole 100 mg twice daily for 3 days for pinworm (or single 100 mg dose). For other indications, follow standard protocols.
Pregnancy increases clearance of aspirin and carisoprodol; however, avoid use due to fetal risks. No recommended dose adjustments; contraindicated, especially in third trimester.
EMVERM (mebendazole) is poorly absorbed systemically, making it ideal for intraluminal helminth infections. Administer with fatty meal to enhance absorption when systemic effect (e.g., for trichinosis) is desired. Avoid in pregnancy (FDA Category C). Tablets may be chewed, swallowed, or crushed. Monitor for rare agranulocytosis, especially with concurrent metronidazole or high doses.
Carisoprodol is metabolized to meprobamate, a controlled substance; monitor for abuse potential. Aspirin increases bleeding risk; avoid in children with viral illness due to Reye's syndrome. Combination may cause CNS depression and impaired motor function. Use with caution in renal impairment.
Take exactly as prescribed; a second course may be needed if reinfection occurs.,Tablets can be chewed, crushed, or swallowed whole with or without food.,Mebendazole works by preventing worms from absorbing sugar, causing their death.,Strict hand hygiene and laundering of bedding/clothing to prevent reinfection.,Treat all household members if pinworm outbreak; withhold treatment in pregnancy unless essential.,Notify provider if fever, sore throat, or unusual bleeding/bruising (agranulocytosis warning).
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Take with food or milk to reduce stomach upset.,Do not use in children or teenagers with flu-like symptoms or chickenpox due to risk of Reye's syndrome.,Report signs of bleeding (easy bruising, black stools, vomiting blood) or allergic reactions (rash, swelling, difficulty breathing).,Rapid discontinuation may cause withdrawal symptoms (anxiety, insomnia, muscle twitching).
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMVERM vs CARISOPRODOL AND ASPIRIN, answered by our medical review team.
EMVERM is a Anthelmintic that works by Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.. CARISOPRODOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMVERM and CARISOPRODOL AND ASPIRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMVERM is: Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.. The standard adult dose of CARISOPRODOL AND ASPIRIN is: 1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMVERM and CARISOPRODOL AND ASPIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMVERM is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed.. CARISOPRODOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.